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Abstract
The Consortium for Improving Survival of Lymphoma (CISL) in Korean Society of 
Hematology Lymphoma Working Party had first meeting in February, 2006 with 10 in-
stitutions and 12 members. Now CISL comprised of 64 centers. CISL has concentrated 
research activity on lymphomas which are relatively frequent in Korea and has tried to 
give favors for the Korean lymphoma patients. CISL has conducted more than 30 retro-
spective studies to evaluate Korean peculiar lymphoma subtypes. More than 30 pro-
spective trials have been being performed for diffuse large B-cell lymphoma, marginal 
zone lymphoma, extra-nodal NK/T-cell lymphoma, and so on. The first prospective trial 
for advanced marginal zone lymphoma has led to use Rituximab containing chemo-
therapy with the re-imbursement of health insurance in Korea. The multi-center trials of 
the CISL with new therapeutic modalities will improve further the survival of lymphoma 
patients not only quantitatively but also qualitatively.
Key Words Lymphoma, KSH, Lymhoma working party, CISL
Correspondence to
Cheolwon Suh, M.D., Ph.D.
Department of Oncology, Asan Medical 
Center, University of Ulsan College of 
Medicine, 88, Olympic-ro 43-gil, 
Songpa-gu, Seoul 138-736, Korea
Tel: ＋82-2-3010-3209
Fax: ＋82-2-3010-6961
E-mail: csuh@amc.seoul.kr
Ⓒ 2013 Korean Society of Hematology
INTRODUCTION
Lymphomas are clonal neoplasms of B cells, T cells, or 
natural killer (NK) cells [1, 2]. Recently, changes in how 
lymphomas are classified, proposals for new subtype entities, 
and the development of innovative treatment modalities that 
utilize novel therapeutic agents have stimulated a paradigm 
shift in the diagnosis and management of lymphomas [3]. 
Accompanying these advances, the Consortium for Improv-
ing Survival of Lymphoma (CISL) of the Korean Society 
of Hematology Lymphoma Working Party (KLWP) first met 
in 2006. CISL has concentrated its attention on the types 
of lymphoma that occur most frequently in the Korean pop-
ulation and their unique features and has tried to conduct 
research that could be of benefit to Korean patients with 
lymphoma. Here, we summarize the clinical studies per-
formed by CISL.
THE HISTORY OF KLWP-CISL
KLWP, founded in October 2005, is responsible not only 
for trials against lymphoma but also for administrative work, 
patient education, and other work/projects related to lym-
phoma control and treatment in Korea. With the need for 
more comprehensive and active clinical research, we formed 
a clinical study group for lymphoma. In the first CISL meet-
ing, conducted in February 2006, 12 members participated 
from 10 institutions. Since then, CISL has held research 
meetings twice a year and now comprises 130 scholars and 
80 clinical research coordinators from 64 institutions. Since 
2011, CISL has also run a central office that undertakes 
administrative work. However, the consortium requires 
much more funding in order to perform better prospective 
clinical trials and improve organization. Despite these limi-
tations, CISL has conducted more than 30 retrospective stud-
ies to evaluate unique clinical and pathological features of 
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lymphoma subtypes that are more frequent in Korea than 
in other countries. CISL has also performed more than 30 
prospective trials on diffuse large B-cell lymphoma (DLBCL), 
marginal zone lymphoma (MZL), and extra-nodal NK/T-cell 
lymphoma (ENNKTCL). As of December 2012, CISL had 
published 35 articles in internationally renowned, peer-re-
viewed journals, as well as in the Korean journals, and these 
will be discussed here.
CISL also collaborates with foreign lymphoma study 
groups. These include the Groupe d’Etudes des Lymphomes 
de l’Adulte, which developed the rituximab plus cyclophos-
phamide, doxorubicin, vincristine, and prednisone (R-CHOP) 
regimen for the treatment of DLBCL; the German High- 
Grade Non-Hodgkin Lymphoma Study Group, which per-
formed the RICOVER trial on young patients with DLBCL; 
the International Extranodal Lymphoma Study Group, whose 
work focuses on extranodal lymphomas; and the Lymphoma 
Study Group of the Japan Clinical Oncology Group, which 
is one of the leading lymphoma study groups in Japan and 
has conducted a DLBCL study with CISL. KLWP holds the 
Asian Lymphoma Forum annually for the international coor-
dination of CISL activity.
RETROSPECTIVE STUDIES
1. MZL
CISL has published several retrospective studies of MZL 
[4-12] and also published a review article [13]. MZL repre-
sents a distinct subgroup of non-Hodgkin lymphoma (NHL), 
which is typically characterized by an indolent clinical course 
and long survival times. CISL has shown that MZL comprises 
17.3% of NHLs, while mucosa-associated lymphoid tissue 
lymphoma accounts for 16.7% and nodal MZL accounts for 
0.6% of all NHLs. MZL is the second most frequent histologic 
lymphoma subtype after DLBCL in Korea. Gastric MZL ac-
counts for 50% of all patients with MZL in Korea. In patients 
with non-gastric MZL, the most commonly involved sites 
are (in decreasing order of frequency) the orbit and ocular 
adnexa (48.9%), lymph node and lymphatic organs (17.8%), 
bowel (9.3%), lungs (6.1%), thyroid (4.9%), and salivary 
glands (4.5%). In a retrospective multivariate analysis, nodal 
type compared to extranodal MZL, advanced stage, and poor 
performance were predictive of poor survival in patients 
with non-gastric MZL. The clinical features of primary 
site-specific MZL have been reported for the thyroid, intes-
tine, lungs, and synchronous multiple primary sites involve-
ment.
2. DLBCL
CISL has carried out retrospective studies on some specific 
primary sites of DLBCL. Retrospective analysis of primary 
breast DLBCL suggested that the patient group with one 
extranodal disease in the breast, compared to those with 
multiple extranodal diseases, had a different treatment out-
come, prognosis, and pattern of progression, and patients 
with one extranodal disease in the breast should be consid-
ered primary breast lymphoma in future trials [14].
CISL also conducted a matched pair analysis of primary 
breast DLBCL and nodal DLBCL [15]. This report suggested 
that clinical outcomes of primary breast DLBCL might no 
longer be worse than those of nodal DLBCL in the rituximab 
era; however, even when taking rituximab treatment into 
account, extranodal progressions in the breast or central 
nervous system (CNS) are problematic.
Intestinal DLBCL was also studied retrospectively [16]. 
CISL concluded that surgical resection followed by chemo-
therapy might be an effective treatment strategy with accept-
able levels of life quality deterioration for localized intestinal 
DLBCL.
CISL has also studied primary adrenal DLBCL [17]. We 
showed that outcomes of primary adrenal DLBCL treated 
with the R-CHOP regimen are encouraging and that achiev-
ing complete response after R-CHOP is predictive of survival. 
A modified staging system was also suggested.
3. Others
In a retrospective analysis of 208 patients with ENNKTCL 
from multiple CISL centers, we suggested that CNS evalua-
tion and prophylaxis do not seem to be necessary in NK 
prognostic index group I or II patients owing to a very 
low incidence, despite the fact that ENNKTCL frequently 
involves the paranasal sinuses [18]. Nevertheless, CNS pro-
phylaxis should be considered as a treatment for patients 
in NK prognostic index groups III and IV [19]. A multina-
tional retrospective analysis was undertaken to evaluate the 
clinical features and outcomes of ENNKTCL arising from 
extranasal sites [20]. We suggested a treatment recommend-
ation according to tumor-node-metastasis stage. Radiother-
apy with or without chemotherapy seemed to be optimal 
in localized disease. In advanced stages, a more aggressive 
treatment regimen with newer agents should be sought.
For peripheral T-cell lymphoma (PTCL), CISL has reported 
2 retrospective studies. In one report, lymphopenia was sug-
gested to be an independent prognostic marker that predicted 
unfavorable survival in patients with PTCL treated with 
anthracycline-containing chemotherapy and can be used to 
further stratify high-risk patients using International Pro-
gnostic Index scores [21]. A multinational retrospective study 
was performed with a focus on non-bacterial infections in 
patients receiving alemtuzumab. Based on that report, CISL 
has constructed a guideline for antimicrobial prophylaxis 
in patients receiving alemtuzumab therapy [22].
Clinical features of some specific sites involved in lympho-
ma were assessed retrospectively.
A study dealing with ovary involvement showed that treat-
ment outcomes of secondary ovarian involvement in NHL 
were comparable to those of primary ovarian involvement. 
We suggested that ovarian involvement itself does not neces-
sarily predict a worse prognosis for patients with NHL [23].
CISL retrospectively analyzed 581 patients from 16 hospi-
tals in Korea for primary intestinal NHL and compared clin-
ical features and treatment outcomes according to the ana-
tomic site of involvement and histologic subtypes. The sur-
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Fig. 1. Chronological flow of prospective CISL studies. Abbreviations: DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; MZL, 
marginal zone lymphoma; OAML, ocular adnexa MZL; ENNKTCL, extranodal NK/T cell lymphoma; T-cell, T-cell lymphomas; HL, Hodgkin 
lymphoma; CNS, central nervous system; ASCT, autologous stem cell transplantation. CISL 0601, concurrent chemo-radiotherapy (CCRT) and 
weekly cisplatin followed by VIPD (etoposide, ifosfamide, cisplatin, and dexamethasone); CISL 0602, radioimmunotherapy with 131I-rituximab; 
CISL 0603, bortezomib plus CHOP (cyclophosphamide, adriamycin, vincristine, and prednisolone) every 2 weeks; CISL 0604, alemtuzumab plus 
and DHAP (dexamethasone, high-dose cytarabine, and cisplatin); CISL 0605, rituximab (R) plus CVP (cyclophosphamide, vincristine, and 
prednisolone); CISL 0606, gemcitabine single agent; CISL 0607, yttrium-90 ibritumomab tiuxetan consolidation following rituximab plus CHOP; 
CISL 0701, bortezomib plus CHOP; CISL 0702, GIDOX (gemcitabine, ifosfamide, dexamethasone, and oxaliplatin); CISL 0801, CCRT followed by 
VIDL (etoposide, ifosfamide, dexamethasone, and L-asparaginase) with risk-based application of ASCT; CISL 0802, ESHAOX (etoposide, 
methylprednisolone, high-dose cytarabine, and oxaliplatin); CISL 0803, intensified 1st cycle R plus 8 cycles of R-CHOP, CISL 0806 and 0901, 
busulfan, melphalan, and etoposide as conditioning; CISL 0905, Ox-P (oxaliplatin and prednisolone); CISL 1001, high-dose methotrexate induction
followed by alternative high-dose methotrexate and high-dose cytarabine combination consolidation; CISL 1003, GDP (gemcitabine, 
dexamethasone, and cisplatin); CISL 1004, R augmentation following R-CHOP induction; CISL 1006 and 1107, prospective cohort study with 
risk-adapted CNS and bone marrow evaluation; CISL 1008, CCRT followed by MIDLE (methotrexate, ifosfamide, dexamethasone, L-asparaginase, 
and etoposide); CISL 1009, R-CVP followed by R maintenance; CISL 1010, R-CVP; CISL 1011, ESHAOX (etoposide, methylprednisolone, high-dose 
cytarabine, and oxaliplatin); CISL 1106, R-CHOP and prophylactic intrathecal methotrexate; CISL 1108, everolimus plus CHOP; CISL 1201, 
vorinostat plus fludarabine, mitoxantrone, and dexamethasone; CISL 1205, comparison intravenous busulfan, melphalan, and etoposide versus 
intravenous busulfan, cyclophosphamide, and etoposide as conditioning regimen; CISL 1206, R plus reduced dose CHOP for elderly.
vival of patients with ileocecal region involvement was better 
than those with involvement of other sites, which might 
be related to histologic distribution, tumor stage, and the 
need for surgical resection [24].
We studied 539 patients with Hodgkin lymphoma from 
16 centers in Korea retrospectively, and concluded that, de-
spite the lower incidence in Korea than in Western countries, 
the distribution of morphological subtypes, treatment out-
comes, and patient prognoses were similar [25].
Fifty-five newly diagnosed patients with lymphoblastic 
lymphoma were analyzed, and CISL concluded that clinical 
features and treatment outcomes of Korean adult lympho-
blastic lymphoma were comparable to previous results, and 
that the prognosis is still poor, even if treated with intensive 
chemotherapy [26].
PROSPECTIVE STUDIES
1. MZL
A prospective phase II trial of rituximab with cyclo-
phosphamide, vincristine, and prednisolone (R-CVP) as a 
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first-line treatment for advanced-stage MZL was initiated 
in 2006 (Fig. 1, CISL 0605) [27]. Between March 2006 and 
July 2008, 42 patients were enrolled in this trial from 13 
institutions. Overall response rate was 87.5% with complete 
response of 60% and partial response of 27.5%. Toxicity 
was acceptable, with no treatment-related deaths. The esti-
mated 3-year progression-free survival and overall survival 
rates were 59.5% and 95.0%, respectively. Although defining 
the value of rituximab is difficult in a single-arm phase II 
trial, this study concluded that the R-CVP regimen appears 
to be effective and well tolerated in patients with ad-
vanced-stage MZL. This has led to health insurance re-im-
bursement of the R-CVP regimen for patients with advanced 
stage MZL in Korea.
CISL has concurrently conducted a multi-center phase 
II trial to assess the efficacy and safety of gemcitabine single 
chemotherapy for patients with MZL in relapse or refractory 
status (Fig. 1, CISL 0606) [28]. In total, 16 patients were 
enrolled from 6 institutions. There were 2 cases of partial 
responses, 9 cases of stable disease, and 1 case of progression. 
Toxicities were mild and tolerable with no treatment-related 
deaths. As the response rate in stage I of the trial did not 
justify progressing to stage II of the trial, this study had 
to be discontinued in accordance with established protocols. 
It was suggested that gemcitabine as a single agent showed 
minimal clinical activity in cases of relapsed or refractory 
MZL.
2. DLBCL
In 2006, CISL began a phase I/II study of advanced stage 
DLBCL (Fig. 1, CISL 0603). The safety and efficacy of bortezo-
mib treatment with dose-dense CHOP every 2 weeks were 
evaluated. The phase I result recommended a bortezomib 
dose of 1.6 mg/m2 for phase II. In phase II, the overall 
response rate was 95% (complete response: 80%; partial re-
sponse: 15%). Severe sensory neuropathy was the main tox-
icity in this trial. We concluded that bortezomib plus 
CHOP-14 is highly effective but, in many cases, dose or 
schedule modification is required to reduce neurotoxicity 
[29].
The clinical efficacy and safety of yttrium-90 ibritumomab 
tiuxetan (Zevalin) consolidation treatment following R- 
CHOP chemotherapy was investigated in patients with lim-
ited-stage and bulky DLBCL (Fig. 1, CISL 0607). This pro-
spective, multi-center, pilot trial included 21 patients, who 
achieved complete or partial response after 6 cycles of 
R-CHOP. The overall response rate after Zevalin con-
solidation treatment was 80.9%, including 4.8% cases of par-
tial response. The 3-year overall and progression-free survival 
rates were 85% and 75%, respectively. Grade 3–4 adverse 
events were mainly hematologic toxicities; thus, Zevalin con-
solidation following 6 cycles of R-CHOP resulted in an ac-
ceptable response with tolerable toxicity [30].
CISL conducted a prospective phase II trial for patients 
with relapsed or refractory DLBCL (Fig. 1, CISL 0802). We 
investigated a regimen of etoposide, methylprednisolone, 
high-dose cytarabine, and oxaliplatin (ESHAOx). The overall 
response rate was 63%, with 33% of participants showing 
complete response. The most common toxicities were hema-
tologic, and no patient experienced grade 3/4 renal or 
neurotoxicity. ESHAOx was assumed to be an alternative 
option for patients with refractory/relapsed DLBCL [31].
Consequently, salvage therapy with gemcitabine, ifosfa-
mide, dexamethasone, and oxaliplatin (GIDOX) for relapsed 
or refractory DLBCL was tested (Fig. 1, CISL 0702). Twenty- 
seven eligible patients were recruited and 15% showed a 
complete response, while 37% showed a partial response. 
CISL concluded that GIDOX is an active salvage regimen 
for DLBCL and has acceptable levels of toxicity [32].
A radioimmunotherapy trial was performed for salvage 
modality in B-cell NHL (Fig. 1, CISL 0602). Radioiodinated 
rituximab (median dose: 7.3 GBq) was administered in 24 
patients, including 11 with DLBCL. The overall response 
rate was 29%; 46% in patients with low grade B-cell NHL 
and 9% (one partial response) in patients with DLBCL. Grades 
3–4 thrombocytopenia and neutropenia occurred in 33% 
and 21% of patients with B-cell NHL and DLBCL, res-
pectively. This study concluded that radioimmunotherapy 
with radioiodinated rituximab seems to be effective and toler-
able with modest activity in patients with refractory DLBCL. 
Further studies are warranted to determine the efficacy of 
radioiodinated rituximab for treating patients with DLBCL 
[33].
Based on CISL’s 0602 study, CISL conducted a trial of 
repeated radioimmunotherapy for B-cell NHL (Fig. 1, CISL 
1013). Thirty-one patients with relapsed or refractory B-cell 
NHL, including 7 patients with DLBCL, received radio-
immunotherapy repeated at 4-week intervals. A total of 87 
cycles were administered and yielded 2-fold increases in 
response rate (68%) and in median response duration (8.6 
months) compared to a single radioimmunotherapy. This 
regimen induced a favorable response in patients with an 
aggressive histology compared to that induced by a single 
treatment [34].
3. ENNKTCL
Based on the proven benefits of frontline radiation in 
early-stage ENNKTCL, CISL conducted a phase II trial of 
concurrent chemoradiotherapy (CCRT) followed by 3 cycles 
of etoposide, ifosfamide, cisplatin, and dexamethasone (Fig. 
1, CISL 0601). All 30 patients completed CCRT, which re-
sulted in 100% response rate that included 22 complete re-
sponses and 8 partial responses. Twenty-six of 30 patients 
completed the scheduled 3 cycles of chemotherapy. The 
overall response rate after completion of chemotherapy was 
83.3%, with 80% showing complete response. Only 1 patient 
experienced grade 3 nausea during CCRT, whereas 12 of 
29 patients experienced grade 4 neutropenia. The estimated 
3-year progression-free and overall survival rates were 85% 
and 86%, respectively. CISL concluded that patients with 
newly diagnosed, stages IE to IIE, nasal ENNKTCL are best 
treated with frontline CCRT [35].
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Table 1. Published reports of CISL trials according to lymphoma 
subtypes and study types.
Entity
Prospective
Retrospective Total
First line Salvage
NHL DLBCL 2 4   4 10
MCL
MZL 2 10 12
NKT 1   2   3
T-cell 2 1   2   5
Others   2   2
HL   1   1
LBL/BL   1   1
ASCT 1   1
Total 7 6 22 35
Abbreviations: NHL, non-Hodgkin lymphoma; DLBCL, diffuse 
large B-cell lymphoma; MCL, mantle cell lymphoma; MZL, 
marginal zone lymphoma; NKT, extranodal NK/T cell lymphoma; 
T-cell, T-cell lymphomas; HL, Hodgkin lymphoma; LBL, lympho-
blastic lymphoma; BL, Burkitt lymphoma; ASCT, autologous stem 
cell transplantation.
4. T-cell lymphomas
CISL has conducted a phase I trial with bortezomib and 
CHOP as first-line therapy in advanced, aggressive T-cell 
lymphoma (Fig. 1, CISL 0701). Patients received increasing 
doses of bortezomib on days 1 and 8 (weekly schedule: 1.0, 
1.3, and 1.6 mg/m2/dose) in addition to CHOP every 3 weeks, 
and were scheduled for 6 cycles. No dose-limiting non-hema-
tologic toxicity was reported. The maximum-tolerated dose 
was not reached at 1.6 mg/m2, and the complete response 
rate was 62%. We concluded that bortezomib can be safely 
combined with CHOP chemotherapy and constitutes an ac-
tive regimen for patients with advanced-stage, aggressive 
T-cell lymphoma. The recommended dose for subsequent 
phase II studies of bortezomib plus CHOP is 1.6 mg/m2 
on days 1 and 8 every 3 weeks as first-line treatment [36].
Based on the results of this phase I study, we consequently 
performed a phase II trial of bortezomib plus CHOP as the 
first-line treatment for advanced PTCLs. Forty-six patients 
were enrolled, and 30 patients (65%) achieved complete 
response, with an overall response rate of 76%. However, 
the 3-year overall survival and progression- free survival 
were 47% and 35%, respectively, owing to frequent relapse 
after remission. Grade 3/4 leucopenia was the most frequent 
toxicity, whereas neurotoxicity was tolerable (grade 1 or 
2 of peripheral neuropathy). We concluded that bortezomib 
plus CHOP is an effective and feasible regimen for ad-
vanced-stage PTCLs other than ENNKTCL, with acceptable 
toxicity. However, future studies exploring new drug combi-
nations are warranted to overcome relapse after remission 
[37].
We designed a salvage regimen combining alemtuzumab 
with dexamethasone, cisplatin, and cytarabine (DHAP; Fig. 
1, CISL 0604). A total of 16 patients with relapsed or re-
fractory PTCL were enrolled, and the overall response rate 
was 86% for PTCL, unspecified (PTCL-U) which was much 
higher than 14% in ENNKTCL. Myelosuppression and in-
fectious complications, including cytomegalovirus reactiv-
ation were major toxic effects. CISL concluded that alemtuzu-
mab plus DHAP might be an effective salvage chemotherapy 
regimen for patients with PTCL-U, but that caution is recom-
mended in light of potential infectious complications [38].
5. Autologous stem cell transplantation (ASCT)
CISL has developed a protocol using intravenous busulfan, 
melphalan, and thiotepa as a conditioning regimen for 
high-dose therapy in patients with high-risk or relapsed 
NHL (Fig. 1, CISL 0806). Four out of 5 patients with partial 
response before ASCT achieved complete response after 
ASCT, and 10 out of 12 patients achieved or maintained 
complete response after ASCT. However, grade 3–4 mucositis 
and liver toxicity occurred in 65%, and venoocclusive disease 
developed in 46%. We conclude that this regimen is too 
toxic for our patients [39].
THE FUTURE OF KLWP-CISL
CISL has conducted and reported 13 prospective trials, 
while 22 retrospective studies have been performed and pub-
lished (Table 1). CISL is currently undertaking 12 on-going 
prospective trials, and the flow of CISL studies is summarized 
in Fig. 1.
CISL intends to continue to focus on lymphoma subtypes 
relatively common in Korea, namely MZL, ENNKTCL, and 
PTCL, in addition to DLBCL. Clinical trials for lymphoma 
require the collaboration of specialists including pathologists, 
radiologists, radiotherapists, and diagnostic laboratory 
experts. CISL is trying to create a strong collaborative net-
work with these specialists. We also intend to focus on in-
troducing new drugs and treatment regimens to Korean pa-
tients with lymphoma through industry-supported trials or 
CISL’s own studies.
CISL research is currently facing severe challenges. 
Inappropriately strict regulations and shortages of research 
funding prevent CISL from performing further clinical trials 
that could significantly improve survival and quality of life 
for the Korean patients with lymphoma.
Nevertheless, as a member of the Korean Society of 
Hematology Working Parties, CISL will strive to continue 
its work under these difficult circumstances. As its name 
implies, the KLWP-CISL’s core aim is to improve the survival 
of patients with lymphoma.
CONCLUSION
CISL, which was established only 7 years ago, had 35 
publications by the end of 2012. CISL will endeavor to pro-
vide invaluable evidence to improve the clinical course of 
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patients with lymphoma, not only through independent re-
search, but also through collaboration with international 
lymphoma study groups.
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